News

ThermoGenesis Holdings Announces First Quarter 2023 Financial Results and Provides Corporate Update

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., May 15, 2023 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2023 … Continued

ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide a Corporate Strategic Update

Conference Call to be Held on May 15, 2023 RANCHO CORDOVA, Calif., May 10, 2023 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2023 … Continued

ThermoGenesis Holdings Announces Year End 2022 Financial Results and Provides Corporate Update

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., March 30, 2023 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the year ended December 31, 2022 and … Continued

ThermoGenesis Holdings to Announce Financial Results for the Year Ended December 31, 2022 and Provide a Corporate Strategic Update

Conference Call to be Held on March 30, 2023 RANCHO CORDOVA, Calif., March 28, 2023 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the year ended December 31, 2022 and provide a corporate strategic update … Continued

THERMOGENESIS CLOSES $3 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES

RANCHO CORDOVA, CA — March 20, 2023 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced the closing of its previously announced purchase and sale of 1,071,429 shares of its common stock (or common stock equivalents) and warrants to … Continued

THERMOGENESIS ANNOUNCES $3 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES

RANCHO CORDOVA, CA — March 16, 2023 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has entered into definitive agreements for the purchase and sale of 1,071,429 shares of its common stock (or common stock equivalents) … Continued

ThermoGenesis Announces Roll Out of ReadyStart cGMP Suites for Early-Stage Cell and Gene Therapy Companies

RANCHO CORDOVA, Calif., March 15, 2023 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company is rolling out a new facility in the Sacramento metro area, containing a total of 12, class-7, ReadyStart cGMP Suites available for lease … Continued

ThermoGenesis Regains Compliance with Nasdaq Minimum Bid Price Requirement

RANCHO CORDOVA, Calif., January 11, 2023 — ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the “Company”), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price for continued listing on the … Continued

ThermoGenesis Announces 1-for-45 Reverse Stock Split

RANCHO CORDOVA, Calif., December 21, 2022 — ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the “Company”), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced a 1-for-45 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on December 22, 2022.  Beginning tomorrow, December 22, 2022, the Company’s common … Continued

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., November 10, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2022 … Continued

How may we help?